2015年全球、区域及国家层面5岁以下儿童呼吸道合胞病毒所致急性下呼吸道感染的疾病负担估计:一项系统综述与建模研究
该研究通过系统综述1995年1月1日至2016年12月31日发表的文献及76项高质量人群研究数据,采用风险因素模型估计2015年全球5岁以下儿童呼吸道合胞病毒相关急性下呼吸道感染的发病、住院和死亡负担。
要点
- 总体RSV-ALRI死亡可能高达118200例,且发病率和死亡率在不同年份间变化显著。
核心结论
- 全球范围内RSV是儿童ALRI的常见病因和幼儿住院的主要原因,给医疗服务带来巨大负担。
- 约45%的RSV-ALRI住院和院内死亡发生于6月龄以下婴儿。
- 有效的母体RSV疫苗或单克隆抗体可能对该年龄组的疾病负担产生实质性影响。
研究设计与样本
- 系统综述与建模研究,检索1995年1月1日至2016年12月31日发表的文献,并结合76项高质量人群研究的未发表数据。
- 按年龄和世界银行收入区域分层估计5岁以下儿童RSV-ALRI的发病率和住院率。
- 使用基于风险因素的模型和2015年人口估计,估算132个发展中国家的RSV-ALRI发病率。
- 结合院内病死率和住院估计估算院内RSV-ALRI死亡,并通过社区ALRI死亡和RSV活动的月度数据估算总体RSV-ALRI死亡。
主要发现
- 2015年全球5岁以下儿童RSV-ALRI院内死亡59600例(不确定范围48000–74500)。
- 总体RSV-ALRI死亡可能高达118200例(不确定范围94600–149400),且任何特定人群的发病率和死亡率逐年变化显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We have previously estimated that respiratory syncytial virus (RSV) was associated with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) resulting in 55 000 to 199 000 deaths in children younger than 5 years in 2005. In the past 5 years, major research activity on RSV has yielded substantial new data from developing countries. With a considerably expanded dataset from a large international collaboration, we aimed to estimate the global incidence, hospital admission rate, and mortality from RSV-ALRI episodes in young children in 2015. METHODS: We estimated the incidence and hospital admission rate of RSV-associated ALRI (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions from a systematic review of studies published between Jan 1, 1995, and Dec 31, 2016, and unpublished data from 76 high quality population-based studies. We estimated the RSV-ALRI incidence for 132 developing countries using a risk factor-based model and 2015 population estimates. We estimated the in-hospital RSV-ALRI mortality by combining in-hospital case fatality ratios with hospital admission estimates from hospital-based (published and unpublished) studies. We also estimated overall RSV-ALRI mortality by identifying studies reporting monthly data for ALRI mortality in the community and RSV activity. FINDINGS: We estimated that globally in 2015, 33·1 million (uncertainty range [UR] 21·6-50·3) episodes of RSV-ALRI, resulted in about 3·2 million (2·7-3·8) hospital admissions, and 59 600 (48 000-74 500) in-hospital deaths in children younger than 5 years. In children younger than 6 months, 1·4 million (UR 1·2-1·7) hospital admissions, and 27 300 (UR 20 700-36 200) in-hospital deaths were due to RSV-ALRI. We also estimated that the overall RSV-ALRI mortality could be as high as 118 200 (UR 94 600-149 400). Incidence and mortality varied substantially from year to year in any given population. INTERPRETATION: Globally, RSV is a common cause of childhood ALRI and a major cause of hospital admissions in young children, resulting in a substantial burden on health-care services. About 45% of hospital admissions and in-hospital deaths due to RSV-ALRI occur in children younger than 6 months. An effective maternal RSV vaccine or monoclonal antibody could have a substantial effect on disease burden in this age group. FUNDING: The Bill & Melinda Gates Foundation.
引用
- Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017. PMID: 28689664. doi:10.1016/S0140-6736(17)30938-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。